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Abstract The bioavailability of soy isoflavones
depends on the composition of the microflora for each
subject. Bacteria act on different isoflavones with
increased or reduced absorption and cause biotrans-
formation of these compounds into metabolites with
higher biological activity. S-equol is the most impor-
tant metabolite and only 25–65 % of the population
have the microflora that produces this compound. The
presence of equol-producing bacteria in soy product
consumers means that the consumption of such
products for prolonged periods leads to lower cardio-
vascular risk, reduced incidence of prostate and breast
cancer, and greater relief from symptoms related to the
menopause such as hot flushes and osteoporosis.
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Introduction
Isoflavones belong to a group of compounds known as
flavonoids and these share a basic structure that
consists of two benzene rings (A and B) linked through
a heterocyclic pyrone C ring. The benzenoid B ring of
isoflavones is in the 3-position whereas it is in the
2-position in flavones (Franke et al. 2008) (Fig. 1).
Isoflavones are phytoestrogens that are present
almost exclusively in leguminous plants such as
Glycine max, Pueraria mirifica and Trifolium pretense,
amongst others (Kolodziejczyk-Czepas 2012; Malaiv-
ijitnond 2012; Masilamani et al. 2012; Vitale et al.
2012). Glycine max is the most important legume plant
to be used as a food (Young and Bharti 2012) and it also
has the highest concentrations of isoflavones (Crozier
et al. 2009). These compounds are associated with
several health-enhancing properties, such as easing the
symptoms of postmenopausal women, preventing
cardiovascular disease, reducing the risk of osteopo-
rosis, and antimutagenic effects (Chen et al. 2012).
These activities are mainly attributed to the aglycone
forms of isoflavones, which include daidzein, genistein
and glycitein, because it has been demonstrated that
isoflavone aglycones are absorbed more rapidly and in
larger quantities than their glucosides and acetyl and
malonyl-glucoside forms in human intestines (Barnes
et al. 2011). However, isoflavones are present in
soybeans and most soy foods primarily in the glucoside
form (Okabe et al. 2011). Glucoside forms, along with
acetyl and malonyl-glucoside forms, must be
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hydrolyzed by b-glucosidase to produce absorbable
aglycone in the intestinal microflora (Setchell et al.
2002b). Subsequently, some isoflavones are metabo-
lized by the microflora and this results in new
metabolites that have beneficial effects on human
health (Yuan et al. 2007). The composition of each
microflora is very important as the degree of activity of
the resulting compounds depends on this factor.
The human body is a super-organism that contains
10 times more microbial cells than body cells. The
metagenomic study of the human microbiome has
demonstrated that there are 3.3 million unique genes in
the human gut, i.e., 150 times more genes than our own
genome, and bacterial diversity analysis has shown that
around 1,000 bacterial species are living in our gut and
the majority of them belong to the divisions of
Firmicutes and Bacteroidetes (Zhu et al. 2010). The
human gastrointestinal tract harbors the most complex
human microbial ecosystem (Maccaferri et al. 2011).
Depending on the composition of the core of the gut
microflora, Arumugan et al. (2011) revealed that the 33
samples formed three distinct clusters that were
designated as enterotypes by multidimensional cluster
analysis and principal component analysis. These three
enterotypes can be identified by variations in the levels
of one of three genera: Bacteroides (enterotype 1),
Prevotella (enterotype 2) and Ruminococcus (entero-
type 3). A controlled-feeding study (Wu et al. 2011)
associated the Prevotella enterotype with a high-
carbohydrate diet and Bacteroides with high animal fat
and protein consumption. Short-term enforced dietary
shifts from high-fat and high-protein to high-carbohy-
drate, and vice versa, somewhat modified organismal
abundances but rarely changed the presence or absence
of specific gut microbes in particular subjects. Bacteria
that form part of these enterotypes could act in different
ways on components of soy products.
Hydrolysis of glucoside forms
Isoflavones in soybeans are found in four chemical
forms: aglycone, glucoside, acetylglucoside and
malonylglucoside. Examples of compounds that have
been reported include the aglycones daidzein (40,7-
dihydroxyisoflavone), genistein (40,5,7-trihydroxyisof-
lavone) and glycitein (40,7-dihydroxy-6-ethoxyisofla-
vone) and the glucosides daidzin (daidzein
7-glucoside), genistin (genistein 7-glucoside) and glyc-
itin (glycitein 7-glucoside) and their corresponding
acetylglucoside and malonylglucosides: 600-O-acetyl-7-
O-b-D-glucosides (acetyl daidzin, acetyl genistin and
acetyl glycitin), and 600-O-malonyl-7-O-b-D-glucosides
(malonyl daidzin, malonyl genistin, and malonyl glyc-
itin) (Peñalvo et al. 2004).
Isoflavone aglycones are the bioactive forms,
whereas the b-glucoside forms are predominant in
the soybean. The latter compounds must be hydro-
lyzed to be absorbed across the enterocyte of healthy
adults because of their higher molecular weight and
hydrophilicity (Izumi et al. 2000). The b-glucosidase
present in microflora partially hydrolyzes the gluco-
side forms to aglycones in the small intestine, and to a
greater extent in the jejunum, to release the isoflavone
aglycones, which can be absorbed through the gut
epithelium (Setchell et al. 2002b). A proportion of the
isoflavones, which are neither hydrolyzed nor
absorbed in the small intestine, reaches the colon
together with an amount that is excreted into the small
intestine through enterohepatic circulation. In the
colon, the glucuronidated and sulfated isoflavones,
along with the glucoside forms, are hydrolyzed by
bacterial enzymes (b-glucosidase and b-glucuroni-
dase) and then absorbed or subjected to further
metabolism by the intestinal microflora (Doerge
et al. 2000; Zhang et al. 2003) (Fig. 2).
b-glucosidases (b-D-glucoside glucohydrolase, EC
3.2.1.21), which catalyze the hydrolysis of b-gluco-
sidic linkages of various oligosaccharides and gluco-
sides to form glucose and a shorter/debranched
oligosaccharide, have attracted considerable interest
in recent years due to their important roles in various
biological processes, such as the hydrolysis of iso-
flavone glucosides (Matsuura and Obata 1993). These
enzymes are found both free and in bacteria present in
the intestinal microflora. In the intestinal tract the
bacterial metabolism is higher than that of nonbacte-
rial enzymes. Additionally, the hydrolysis rate varies
through the gastrointestinal tract due to changes in the
microflora composition (Turner et al. 2003). The
microorganisms that have strong b-glucosidase activ-
ity are lactic acid bacteria, obligate anaerobes and
Fig. 1 Structure of
isoflavones
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Escherichia coli, all of which colonize the small
intestine.
In several studies lactic acid bacteria such as
Lactobacillus have proven to be excellent probiotics
since they have b-glucosidase activity. Species such as
Lactobacillus rhamnosus, Lactobacillus acidophilus,
Lactobacillus bulgaricus, Lactobacillus casei, Lacto-
bacillus plantarum and Lactobacillus fermentum were
found to have the ability to hydrolyze isoflavone
glucosides to aglycones to a significant extent
([95 %) when the conversions of daidzin and genistin
were quantified (Otieno and Shah 2007; Rekha and
Vijayalakshmi 2011; Marazza et al. 2012). Malashree
et al. (2012) isolated five L. rhamnosus from soymilk
and these have different isoflavone biotransformation
potentials, with a two to threefold increase in genistein
and a 6- to 14-fold increase in daidzein. This finding
confirms that the degree of biotransformation of
isoflavones is characteristic of an individual strain.
In one study it was found that L. rhamnosus JCM 2771,
in addition to the conversion of daidzin into daidzein,
also produced genistein from daidzin (Tamura et al.
2011).
One of the major lactic acid bacterial groups of the
gut microflora in humans is Bifidobacteria. These
bacteria are among the first colonizers of the sterile
gastrointestinal tract of newborns. In a similar way to
Lactobacillus, they have beneficial effects on their
host as they act as probiotics. Almost all strains of
Bifidobacteria have these enzymes, although the
hydrolysis rate is very variable. Raimondi et al.
(2009) studied 22 strains and most of them released
aglycone from daidzin and 12 strains gave yields
higher than 90 %. The enzyme activity of these
bacteria can vary depending on the glucoside forms.
Thus, Bifidobacterium animalis, one of the most
widely studied strains, hydrolyzes isoflavone gluco-
sides and this biotransformation is higher in daidzin
(Tsangalis et al. 2005; Chien et al. 2006; Otieno and
Shah 2007; Pham and Shah 2007; Youn 2012). On the
other hand, a study involving five strains of microor-
ganisms (Lactobacillus paracasei, L. acidophilus and
Bifidobacterium longun) showed a significant increase
in the range 62–96 % in bioactive isoflavone agly-
cones in fermented soymilk with the highest value for
genistin (Wei et al. 2007).
Fig. 2 Structures of isoflavone aglycones and their glucoside derivatives
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Other lactic acid bacteria, namely Enterococcus
faecalis and Streptococcus bovis, also metabolized
isoflavone glucosides to their aglycones (daidzein and
genistein) (Tsuchihashi et al. 2008).
The obligate anaerobes Bacteroides distasonis,
Bacteroides ovatus, Bacteroides fragilis, Clostridium
ramosum, Peptostreptococcus productus and Copro-
bacillus sp., showed high production rates for daidzein
and genistein, while Bacteroides vulgatus, Clostrid-
ium spiroforme, Fusobacterium nucleatum and Pep-
tostreptococcus hydrogenalis did not metabolize soy
isoflavone glucosides at all. The bacteria Mitsuokella
multacida, Prevotella veroralis and Clostridium cel-
atum could not appreciably convert soy isoflavone into
aglycones (Tamura et al. 2007; Tsuchihashi et al.
2008).
Escherichia coli is the most important Enterobac-
teriaceae and it is a commensal bacteria of colonic
microflora (Parkar et al. 2008). Hur et al. (2000)
isolated one strain of E. coli HGH21 from human
intestine and this converted daidzin and genistin to
their respective aglycones daidzein and genistein. The
hydrolysis rate by b-glucosidase of E. coli also
depends on the type of isoflavone, with the highest
hydrolysis rate produced when b-glucosides are not
bonded to malonyl or acetyl moieties. Additionally,
the activity on daidzin and genistin is higher than on
glycitin (Ismail and Hayes 2005). Other authors did
not find activity on glucoside isoflavones (daidzin and
genistin) in some strains of E. coli and in other
Enterobacteria such as Klebsiella pneumoniae (Tsu-
chihashi et al. 2008).
A number of other microorganisms present in soy
products, such as Aspergillus oryzae, Aspergillus
pulverulentus, Bacillus subtilis and Rhizopus oligosp-
orus (Chiou and Cheng 2001; Mase et al. 2004; Kaya
et al. 2008; Lun-Cheng and Kung-Ta 2008; Horii et al.
2009; Cheng et al. 2010), have been proposed to be
involved in the hydrolysis of isoflavones in the
intestinal microflora.
In general, these enzymes have higher hydrolysis
rates in glucosides rather than malonyl and acetyl
glucosides. It has been suggested that the latter
compounds might be hydrolyzed in distant regions
of the gut where bacterial concentrations are higher
(Barnes et al. 1996). It is likely that the malonyl and
acetyl groups at C-6 of the glucose ring cause ionic or
steric hindrance of the enzyme, thus preventing it from
detaching the glucose from the isoflavone. The lower
conversion of glycitein is probably due to the presence
of the methoxy group at C-6 of the aglycone ring,
which would also cause ionic or steric hindrance of the
enzyme. Thus, the bacterial b-glucosidases present in
the human gut could have variable activity toward the
different forms of glycosides and this in turn would
affect their rates of hydrolysis.
Changes in the intestinal microflora could also
affect the hydrolysis of isoflavones and thus affect the
bioavailability of these phytoestrogens. Therefore,
diseases that produce dysbiosis of gut microflora, such
as inflammatory bowel disease, irritable bowel syn-
drome, necrotizing enterocolitis, celiac disease, colo-
rectal cancer, obesity, metabolic syndrome and
diabetes (Marteau 2009; Walker et al. 2011; Chassard
et al. 2012; Qin et al. 2012; Smith et al. 2012; Zupancic
et al. 2012; Ohigashi et al. 2013; Sjoberg et al. 2013),
could decrease the bioavailability of isoflavones.
Metabolism of aglycones
Gut microflora play an important role in the metab-
olism of daidzein, which is converted to O-desmethy-
langolensin (ODMA) and the highly active metabolite
S-equol. In addition, dihydrodaidzein (DHD), tetra-
hydrodaidzein, 30-hydroxydaidzein, 6-hydroxydaidz-
ein, 8-hydroxydaidzein, benzopyran-4,7-diol, 3-(4-
hydroxyphenyl) and 2-dehydro-ODMA have also
been reported to be metabolites of daidzein (Rowland
et al. 2000).
Once the daidzein has been absorbed, it is hydro-
genated by bacteria of gut microflora to produce
dihydrodaidzein. Subsequently, DHD can undergo
two processes: reductive cleavage across the hetero-
cycle to produce O-desmethylangolensin and a two-
step deoxygenation to S-equol (Kelly et al. 1995)
(Fig. 3).
Genistein can also be metabolized by gut micro-
flora. Bacteria reduce the double bond between C-2
and C-3 of the C-ring of genistein to a single bond, a
process that results in the formation of dihydrogeni-
stein (Hur et al. 2000). Other bacteria are capable of
biotransforming dihydrogenistein to 5-hydroxy-equol,
a compound that shows a higher antioxidant activity
than genistein (Arora et al. 1998; Matthies et al. 2009).
On the other hand, genistein can be completely
degraded by 60-hydroxy-O-desmethylangolensin to
2-(4-hydroxyphenyl)propionic acid (Schoefer et al.
2002) (Fig. 4).
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Several bacteria have been implicated in the
metabolic pathways of isoflavone aglycones. It is not
completely clear if the conversion of daidzein to S-
equol is performed by a single bacterium or whether
there are a number of bacteria that execute these
reactions. The large variability in the levels of DHD
and S-equol in human urine seem to indicate that there
is more than a single bacterium responsible for
producing S-equol. Furthermore, the finding that
certain antibiotics selectively inhibit the formation of
equol but not dihydrodaidzein when human feces from
equol-producers are incubated with daidzein also
supports this contention (Atkinson et al. 2004). Thus,
there are bacteria that can only convert daidzein to
dihydrodaidzein, while other bacteria can biotrans-
form daidzein to S-equol. Human intestinal bacteria
that can metabolize daidzein are listed in Table 1.
Species that biotransform daidzein into dihydrod-
aidzein are diverse. For example, Park et al. (2011)
found a Gram-negative anaerobic microorganism
(MRG-1) that was identified as a new species with
91.0 % homology to Coprobacillus species isolated
from the human intestine. This microorganism showed
high activities in the deglycosylation and reduction of
daidzin to DHD and stereoselective reductase activity
on isoflavone, daidzein, genistein and 7-hydroxyisof-
lavone, producing the corresponding R-isoflavanone
enantiomers. Under the reported conditions, the Gram-
positive strains HGH6 and TM-40 converted daidzin
to DHD incompletely, although strain HGH6 con-
verted genistein to dihydrogenistein with a yield of
90 % (Hur et al. 2000; Tamura et al. 2007).
Desmethylangolensin is one of the most frequently
isolated metabolites because about 80–90 % of the
human intake of isoflavones are desmethylangolensin
producers (Frankenfeld 2011). Only three bacteria,
Eubacterium ramulus, Clostridium sp. HGH 136 and
Clostridium sp. SY8519, have been described as
producing O-DMA from daidzein (Hur et al. 2002;

































of daidzein by gut
microflora
Phytochem Rev (2013) 12:979–1000 983
123
the high percentage of desmethylangolensin producers
leads us to believe that the number should be higher.
All of these strains are closely related or belong to
Clostridium rRNA cluster XIVa, which is one of the
most abundant phylum in the microflora of the human
intestinal tract (Ringel-Kulka et al. 2013).
Some equol-producing bacteria have also been
isolated. Both single strains, such as the lactic acid
bacteria Slackia sp. and Eggerthella sp., and mixed
cultures convert daidzein to equol (Uchiyama et al.
1999, 2005; Tsangalis et al. 2002; Decroos et al. 2005;
Maruo et al. 2008; Yokoyama and Suzuki 2008; Tsuji
et al. 2010; Tamura et al. 2011). Probiotic bacteria, e.g.
L. rhamnosus, in fecal incubation with daidzein led to
an increase in equol concentration on increasing the
concentration of this microorganism (Tamura et al.
2011). Other lactic acid bacteria, such as Bifidobacte-
rium longum, found in the human gastrointestinal tract
might be involved in the process of transforming
isoflavones to equol. The production of S-equol occurs
predominantly during the exponential growth of this
strain, over the period between 12 and 24 h incubation,
with a subsequent reduction in its formation after 24 h
(Tsangalis et al. 2002). In both cases a higher density of
probiotic bacteria was necessary to produce a high
equol concentration. Other bacteria, such as the genera
Slackia and Eggerthella, belong to the family Corio-
bacteriaceae and these showed good equol-producing
rates from daidzein ([80 %) (Matthies et al. 2009; Jin
et al. 2010; Tsuji et al. 2010). Members of this family
from human feces were capable of metabolizing DHD
to S-equol, although this conversion was only possible
with a specific strain. So, Mauro et al. demonstrated
that only two of the nine strains of Adlercreutzia
equolifaciens gen. nov., sp. nov. (FJC-A10 and FJC-
































Fig. 4 Biotransformation of genistein by gut microflora
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Eggerthella sp. Julong732, an equol-producing bacte-
rium isolated from human feces (Wang et al. 2005).
The other seven isolates could metabolize daidzein to
equol via dihydrodaidzein (Maruo et al. 2008). A stable
mixed microbial culture, consisting of four associated
bacteria that were identified as Enterococcus faecium
strain EPI1, Lactobacillus mucosae strain EPI2, Fine-
goldia magna strain EPI3 and an undescribed species
related to Veillonella sp., was capable of transforming
daidzein into equol. Only the first three bacteria could
be brought in culture individually, but they did not
produce equol or DHD from daidzein. The related
Veillonella sp. bacterium could not be isolated through
conventional plating techniques. When the three
isolated bacteria and the purchased Veillonella sp.
strains were combined, equol production was again not
observed. This could indicate that replacement of the
poorly identified species by the different Veillonella
strains did not mimic the equol-producing mixed
culture. It is possible that one or more species, which
could be present in very small numbers and whose
presence was not detected, contributed to equol
production (Decroos et al. 2005). This possibility is
consistent with another study involving a group of
bacteria that converted daidzein to equol only when all
were present (Uchiyama et al. 1999).
Table 1 Human bacteria
that biotransform isoflavone
aglycones
D Daidzein, E Equol, DHD
dihydrodaidzein, ODMA
O-desmethylangolensin,





Bacterium strain Biotransformation References
Lactobacillus rhamnosus JCM 2771 D ? E Tamura et al.
(2011)
Coprobacillus sp. MRG-1 D ? DHD Park et al. (2011)
Clostridium sp. SY8519 D ? ODMA Yokoyama et al.
(2010)
Slackia sp. NATTS D ? E Tsuji et al. (2010)
Slackia equolifaciens sp. nov., DSM 22006 D ? E Jin et al. (2010)
Slackia isoflavoniconvertens HE8 D ? E Matthies et al.
(2009)G ? 5-OH E
Slackia equolifaciens sp. nov. DZE D ? E Jin et al. (2008)
G ? 5-OH E
Adlercreutzia equolifaciens sp. nov. D ? E Maruo et al.
(2008)DHD ? E
Eggerthella sp. YY7918 D ? E Yokoyama and
Suzuki (2008)
Clostridium sp. TM-40 D ? DHD Tamura et al.
(2007)
Mixed culture (EP4) with Veillonella sp. EP
Enterococcus faecium EPI1 Lactobacillus mucosae
EPI2 Finegoldia magna EPI3
D ? E Decroos et al.
(2005)
Eggerthella sp. Julong 732 DHD ? E Wang et al.
(2005)
Lactococcus garvieae 20–92 D ? E Uchiyama et al.
(2005)
Eubacterium ramulus Julong 601 D ? ODMA Schoefer et al.
(2002)G ? 2-HPPA
Bifidobacterium longum-a D ? E Tsangalis et al.
(2002)
Clostridium sp. HGH 136 D ? ODMA Hur et al. (2002)
Gram-positive HGH6 D ? DHD Hur et al. (2000)
G ? DHG
Group consisting of Bacteroides ovatus E-23-15
Streptococcus intermedius E-23-17
Streptococcus constellatus Abg225
D ? E Uchiyama et al.
(1999)
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While the formation of equol from daidzein via
dihydrodaidzein is catalyzed by several bacterial spe-
cies, the corresponding conversion of genistein to
5-hydroxy-equol has been demonstrated for only two
strains isolated from human feces, HE8 and DZE (Jin
et al. 2008; Matthies et al. 2009). The enrichment of the
intermediate dihydrogenistein in the course of genistein
conversion by strain HE8 was reported previously for
strain HGH6 (Hur et al. 2000). Strain HE8 hardly
converted daidzein and genistein when the isoflavones
were added in the stationary growth phase. The
conversion rates (standard deviations) were 0.16 lmol/
h mg protein for daidzein and 0.20 lmol h/mg protein
for genistein. When the cells were grown in the presence
of daidzein, the conversion rate of daidzein, when added
during the early stationary phase, increased tenfold.
Similarly, the rate of genistein conversion in the
stationary phase increased fivefold when the bacteria
were grown with genistein. In fact, the conversion of
genistein in the stationary phase was increased 12-fold
when strain HE8 had been grown in the presence of
daidzein. The findings suggest that the isoflavone
conversion in other equol-forming intestinal bacteria
is also inducible (Matthies et al. 2009).
S-Equol
Equol [7-hydroxy-3-(40-hydroxyphenyl)-chroman],
an isoflavan, belongs to the general class of com-
pounds referred to as nonsteroidal estrogens. It has a
molecular formula of C15H14O3 and a molecular
weight of 242.27 Daltons. The heterocyclic structure
contains 2 reactive hydroxyls and 1 relatively inert and
unreactive oxygen in the central pyran ring (Setchell
and Clerici 2010). Physicochemically, equol is non-
polar and is relatively insoluble in water. As a result of
the chiral carbon at position C-3 of the molecule, equol
exists in 2 enantiomeric forms, R-equol and S-equol,
and the latter is the natural diastereoisomer produced
by intestinal bacteria in the intestine of humans,
monkeys and rats (Schwen et al. 2012). The 2
enantiomers have been shown to differ in binding
affinities and preferences for estrogen receptor a
(ERa) and ERb; S-equol has a high binding affinity for
and preferentially binds to ERb, whereas R-equol
binds preferentially to ERa (Muthyala et al. 2004).
This affinity is higher than that of daidzein (10–80
times) and it induces transcription more strongly than
any other isoflavone. Therefore, because equol
mediates many of its biological effects by binding to
the estrogen receptors, in vitro studies suggest that
equol is more biologically active than daidzein.
A concentration of[5–10 ng/mL has been associ-
ated with a positive outcome for vasomotor symptoms,
osteoporosis (as measured by an increase in bone
mineral density), prostate cancer, and the cardiovas-
cular risk biomarkers low-density lipoprotein choles-
terol and C-reactive protein.
Equol-producer phenotype
Those people who can metabolize daidzein to equol
are designated ‘equol producers’. Individuals with a
plasma equol concentration of[83 nmol/L (20 mg/L)
are classified as ‘equol producers’ and those with
concentrations \40 nmol/L (10 mg/L) can be classi-
fied as ‘equol non-producers’ (Setchell et al. 2002a).
Cut-off levels can also be applied to urinary concen-
trations, with an equol producer being defined as
excreting[1,000 nmol/L (Rowland et al. 2000).
Some studies have assessed demographic, anthro-
pometric and other lifestyle factors in relation to equol
producer phenotypes.
The percentage of a population that are equol
producers varies according to geographic distribution.
The prevalence of equol producers has been estimated
to be 30–35 % in Western populations and up to 60 %
in vegetarians or Asians (Gardana et al. 2009). This
trend is mainly due to diet, because Asian populations
intake higher amounts of soy products than Western
populations. This fact has been confirmed in several
studies, the results of which suggest that dairy soy
product intake may be associated with the production
of equol (Nagata et al. 2008). Microflora are stable and
characteristic of each subject. Several studies suggest
that the short-term administration of isoflavone sup-
plements can convert equol non-producers to produc-
ers. For example, Tanaka et al. (2009) found that
among 10 equol non-producers, 2 healthy volunteers
became equol producers after supplementation for
3 months.
A person’s weight can have an influence on
microflora. Recently, it has been reported that the
ratio for equol producers in overweight or obese
subject groups was lower (32.1 %) than the previously
reported ratio of equol producers (approximately
50 %) in the Asian general population (Usui et al.
2013). This finding was confirmed in a study of 2,165
986 Phytochem Rev (2013) 12:979–1000
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women who participated in the Shanghai Women’s
Health Study and it was found that urinary excretions
of equol were inversely proportional to body mass
index (Wu et al. 2012).
Although age does not seem to have an influence on
equol production, Fujimoto et al. (2008) found signif-
icant differences in the daily intakes of genistein and
daidzein between the teenager group and the other age
groups C30 years (P \ 0.05). In a study of Japanese
populations, the proportion of equol producers in the
teenager group was 10 % and this is significantly the
lowest level among the age-stratified groups. The
proportions of equol producers in the age-stratified
groups from 10 to 49 years were also significantly
lower than those in their fifties. The equol non-
producers consumed significantly smaller amounts of
isoflavones than the equol producers. In a Korean
population study, the proportions of equol producers
were 45 % in teenagers and 40 % for people in their
twenties and thirties, with both levels significantly
lower than in the groups in their forties (80 %) and
fifties (65 %). The decreased intake of isoflavones,
low serum level of equol and low incidence of equol
production in the younger generation is probably due
to changes in eating habits.
Antibacterial agents used for the treatment of
infections can also alter the composition of bacterial
populations in the colon and therefore can affect
daidzein metabolism. Several antibiotics have been
used to eliminate the colonic bacteria that were
susceptible to these antibiotics. This allowed an
evaluation of the effects of concentrations of antibi-
otics on daidzein metabolism by colonic bacteria in
monkeys and enabled the subpopulation involved in
daidzein metabolism to be identified. Tetracycline
completely removed the equol-producing bacteria; the
metabolism of daidzein was not altered in cultures of
bacteria after ceftriaxone treatment; the bacteria
metabolizing daidzein were enriched by ciprofloxacin.
Therefore, some antibiotics can eliminate equol-
producing bacteria in colonic microflora (Sutherland
et al. 2012).
Antioxidant effects
Studies into the antioxidant activity of both producers
and non-producers of equol have not been carried out
to date. However, equol has shown antioxidant
capacity in several in vivo and in vitro studies.
Antioxidant effects of equol were described in the
1990s and it showed more potent antioxidant activity
than its parent compounds. For example, Arora et al.
(1998) demonstrated that antioxidant activities for the
isoflavone metabolites were comparable or superior to
those of the isoflavone aglycones. Equol and its
4-hydroxy and 5-hydroxy derivatives were the most
potent antioxidants in the study, suggesting that the
absence of the 2,3-double bond and the 4-oxo group on
the isoflavone nucleus enhances antioxidant activity.
Additionally, the number and position of hydroxyl
groups were determining factors for isoflavonoide
antioxidant activity, with hydroxyl substitution being
of high importance at the C-40 position, of moderate
importance at the C-5 position, and of little signifi-
cance at the C-7 position.
The polyphenolic structures of isoflavonoids give
these compounds the ability to scavenge free radicals
and to chelate transition metals, a basis for their potent
antioxidant activities. Is this context, equol signifi-
cantly decreases O2 and H2O2 production in a
concentration-dependent manner (Pereboom et al.
1999). Thus, equol pretreatment caused a decrease in
the H2O2-induced death of bovine aortic endothelial
cells (bAECs) and led to a significant decrease in the
number of cells with apoptotic morphology. This
characteristic probably reduced the production of
intracellular reactive oxygen species (P \ 0.05).
Incubation of bAECs with equol increased the
expression of mitogen-activated protein kinases
(MAPK) p38 and Bcl-2 (B cell lymphoma 2) after
exposure to H2O2 compared with their expression
without the equol pretreatment (Chung et al. 2008).
Equol can act to decrease or increase the availabil-
ity of nitric oxide (NO). NO is a free radical generated
by a family of enzymes called NO synthase (NOS).
The overproduction of NO by inducible NOS (iNOS)
is associated with the development of atherosclerosis.
It has been reported that iNOS knock-out mice
develop reduced levels of atherosclerotic lesion com-
pared to wild-type mice (Buus et al. 2011).
Equol increases NO availability by inhibiting super-
oxide (O2) production and this is manifested through
enhanced levels of free NO, which prevents low-density
lipoprotein (LDL) modification. Pretreatment of cells
with 0.5 lM of equol inhibited production of O2 by J774
monocyte/macrophages (Hwang et al. 2003). To clarify
the effects of equol on oxidized low-density lipoprotein
(OX-LDL), Kamiyama et al. (2009) studied OX-LDL-
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stimulated apoptosis in human umbilical vein endo-
thelial cells (HUVECs) and found that equol inhibited
the induction of apoptosis in response to exposure of
HUVECs to OX-LDL. Treatment of cells with equol
led to a significant reduction in superoxide production
by adenine dinucleotide phosphate (NAD(P)H) oxi-
dase and also to a significant increase in NO produc-
tion. Furthermore, inhibition of LDL oxidation
depends on the isoflavone form. Thus, equol showed
an inhibition of LDL oxidation that was 2.65-fold
better than its parent compound daidzein. 8-Hydrox-
ydaidzein was 12.5-fold better than daidzein while the
parent aglycones also inhibited oxidation, albeit by
only 5 %. However, monosulfated conjugates of
genistein, daidzein and equol were much less effective
and disulfates were completely ineffective. Since
almost all isoflavones circulate as sulfates and glucu-
ronides (conjugated), these data suggest that despite
the increased potency produced by some metabolic
changes, isoflavones may not be effective antioxidants
in vivo unless until they are deconjugated again
(Turner et al. 2004).
Another possible contributory mechanism toward
the antioxidant activities of these compounds is their
ability to stabilize membranes by decreasing mem-
brane fluidity. The effects of equol on membrane
fluidity and their preferential localization in the
membrane were investigated using large unilamellar
vesicles as the membrane models. The results of the
study suggest that equol is partitioned into the
hydrophobic core of the membrane and causes a
dramatic decrease in lipid fluidity in this region of the
membrane. Localization of equol within the mem-
brane interior and the resulting restrictions on fluidity
of membrane components could sterically hinder
diffusion of free radicals and thereby decrease the
kinetics of free radical reactions (Arora et al. 2000).
Antioxidant species may act in vivo to decrease
oxidative damage to DNA, protein and lipids, thus
reducing the risk of coronary heart disease and cancer.
It has been demonstrated in human lymphocytes that
pre-treatment of the cells with equol offered protection
against this damage at concentrations within the
physiological range (Sierens et al. 2001). In another
study it was found that pre-treatment with equol at
doses of 0.01–100 micromol/L significantly protected
sperm DNA against oxidative damage and that equol
is a more potent antioxidant than ascorbic acid and
alpha-tocopherol. It was concluded that this com-
pound could protect against male infertility (Sierens
et al. 2002).
Currently, the most relevant antioxidant mechanism
for equol is protection from photocarcinogenesis,
inflammation and immune suppression induced by
ultraviolet (UV) radiation, so this compound might be
effective in preventing skin cancer or as a sun-protective
cosmetic ingredient. Several models in animals have
been developed to demonstrate the protective effects of
this compound. In hairless mouse, the daily topical
applications of equol lotions significantly protected
against skin carcinogenesis induced by chronic expo-
sure to solar-simulated UV radiation (SSUV), topical
treatment with the chemical carcinogen DMBA or by
the combined cocarcinogenic treatment of DMBA
followed by chronic SSUV (Widyarini et al. 2005).
Additionally, equol was found to have strong antioxi-
dant action against acute UVA-induced lipid peroxida-
tion of mouse skin (Reeve et al. 2005). The
photoimmune protective property was shown to depend
on equol’s activation of estrogen receptor (ERb)
signaling in the skin, which in turn enhances the
expression of antioxidant enzymes and inhibits the
expression of snail, a transcription factor that regulates
keratinocyte cell proliferation and migration (Jackson
et al. 2011). UVB irradiation has also been used to
induce inflammation in mouse skin. It was found that the
effect of topical applications of equol dose-dependently
inhibited the UVB induction of cutaneous tumor
necrosis factor (TNF)-a mRNA and protein, a cytokine
critical for the initiation of psoriatic inflammation.
Expression of IL-6 mRNA and protein was also
decreased and the number of infiltrating mast cells into
the dermis was reduced. Furthermore, the upregulated
mRNA and protein levels of P-cadherin, a marker
characteristic of cutaneous hyperproliferation, were also
normalized. These results suggested that equol has the
potential for useful, innocuous anti-inflammatory ther-
apy from topical application in human cutaneous
diseases (Bandara et al. 2010).
Equol may act as an antioxidant through the
inhibition of oxidative stress and stimulation of
catalase and superoxide dismutase (SOD), but it can
also cause prooxidant effects such as reduction of the
glutathione/glutathione disulfide (GSH/GSSG) ratio
depending on the treatment period. This was demon-
strated in a mouse model in which equol was orally
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administered at either 5 or 25 mg/kg body weight/day
for 1, 3 or 7 weeks. Equol administration significantly
inhibited biomarkers of oxidative stress (i.e., thiobar-
bituric acid-reactive substances value, carbonyl con-
tent, and serum 8-hydroxydeoxyguanosine) at all
doses and for all durations of administration. This
phenomenon was most pronounced at 3 weeks. More-
over, catalase and total SOD activities and their
mRNA expression were significantly increased by
equol. Although equol increased the glutathione
peroxidase (GSH-px) activity in mice treated with
equol for 1 week, long-term administration of equol
(7 weeks) caused a decrease in the ratio of GSH/GSSG
and the activities of GSH-px and glutathione reductase
(Choi 2009b). These findings are consistent with the
results of another study performed in mouse brain, in
which the long-term or higher dose of equol caused
apoptosis (Choi 2009a).
Menopause
Postmenopausal women suffer several symptoms,
such as hot flushes and osteoporosis. Soy food has
proven to be beneficial in postmenopausal subjects,
mainly in Asian countries.
It has been observed that Asian women have fewer
hot flushes than women of other ethnic groups and this
may be explained, at least partially, by both the higher
overall consumption of soy products and the higher
percentage of women able to harbor equol-producing
bacteria in Asia (Gold et al. 2000). In a study of 96
menopausal women from Taiwan, 66 were included in
the isoflavone group and 30 in the placebo group (52 %
equol producers). Compared with the women in the
placebo group, those with the ability to produce equol
experienced a greater and more rapid improvement of
their menopausal symptoms after they began taking a
daily dose of 135 mg of isoflavones. Thus, in the equol
producer group only, the scores for hot flushes and
excessive sweating were significantly reduced after
3 months, as were the scores for weakness, palpita-
tions, limb paresthesia and total symptoms after
6 months (Jou et al. 2008). In another randomized
study on 130 perimenopausal (no menses in the past
3 months) and postmenopausal (C12 months of amen-
orrhea) North American women with a mean of five or
more moderate/severe hot flushes per day, the subjects
were treated with varying total daily isoflavone doses
and dosing frequency, with the study carried out
separately for equol producers and non-producers. Hot
flush intensity scores were lower in women with the
highest total daily dose (100–200 mg) and the highest
dosing frequency (2–3 times daily), with greater
benefits on nighttime scores than on daytime scores.
Dose and frequency related differences were somewhat
larger in equol producers than in non-producers
(Crawford et al. 2013).
To demonstrate effects of equol on hot flushes, two
studies with doses of 10 mg/day of S-equol in
postmenopausal North American and Japanese
women have been carried out. This dose reduced hot
flush frequency and it was even more effective for
relieving muscle and joint pain. Thus, S-equol
(C20 mg/day) alleviates hot flushes to a greater extent
than soy isoflavones in those women who experience
[8 hot flushes/day (Aso et al. 2012; Jenks et al. 2012).
This finding is consistent with the results of a previous
study in an ovariectomized rat model (Yoneda et al.
2011).
It is critical for women to maintain a high bone
mineral density (BMD) prior to menopause to prevent
osteoporosis. In an effort to examine and clarify the
mechanism of the bone-protective effects of isoflav-
ones in humans, several studies were carried out on
both premenopausal and postmenopausal women. A
study of 200 premenopausal women in the United
States without isoflavone supplement intake did not
show differences in hip, spine, femoral neck or head
BMD, or in body composition between equol produc-
ers (27.5 %) and non-producers. This result may be
due to low soy consumption and the low number of
daidzein-metabolizing bacteria in Western premeno-
pausal women (Atkinson et al. 2012). This trend is
consistent with the results of another study of 128
healthy Japanese postmenopausal women aged
45–60 years who were randomly assigned to 4 groups:
placebo; placebo combined with walking (3 times per
week); isoflavone intake (75 mg of isoflavones per
day); and isoflavone combined with walking. The
subjects were classified as producers (55.7 %) or non-
producers of equol. The percentage changes in BMD
in equol producers were -0.53 and ?0.13 % in the
sub-whole body and total hip, respectively. These
results are significantly different to the values of
-1.35 and -1.77 % for the sub-whole body and total
hip, respectively, in non-producers in the isoflavone
group (P = 0.049 and 0.040, respectively). The
findings of this study suggest that the preventive
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effects of isoflavones on bone loss depend on the
individual’s intestinal flora for equol production (Wu
et al. 2006). This finding is similar to that obtained in a
study by Ishimi, in which 54 early postmenopausal
Japanese women were classified by their equol-
producer phenotype. It was found that the annualized
changes in BMD in the total hip and intertrochanteric
regions in the isoflavone-treated equol producers
(-0.46 and -0.04 %, respectively) were lower than
in the non-producers (-2.28 and -2.61 %, respec-
tively) and the annualized change in fat mass was also
lower in the equol producers compared with the non-
producers in the isoflavone group. Equol also inhibited
bone loss and fat accumulation in estrogen-deficient
osteoporotic mice (Ishimi 2010). Furthermore, S-
equol formed from daidzein may play a critical role
in preventing bone loss. In this respect, Tousen et al.
(2011) performed a 1-year double-blind, randomized,
placebo-controlled trial with natural S-equol supple-
ments on 93 non-equol-producing menopausal Japa-
nese women. These women showed a significant
decrease in urinary deoxypyridinoline (a specific
marker of bone resorption and osteoclastic activity)
with a -23.94 % change in the group that received
10 mg of equol supplement per day, compared with a
-2.87 % change in the group that received a placebo,
after 12 months of intervention (P = 0.020). Thus,
10 mg/day of equol supplement markedly inhibited
bone resorption and prevented a decrease in bone
mineral density in the entire body in postmenopausal
women after 12 months.
Modulation of cardiovascular risk
Cardiovascular disease (CVD) mortality rates are
lower in Asian countries where dietary patterns are
very different from those in Western countries.
Previous studies have suggested that the daidzein
metabolite equol rather than daidzein itself contributes
to the beneficial effect of soya foods in the prevention
of CVD. Early studies showed that the intake of
isoflavones reduced some lipid markers in hypercho-
lesterolemic and/or hypertensive volunteers or post-
menopausal women. A study of Asian populations
(202 Chinese adults, 63 % equol producers and 37 %
non-producers equol) showed that equol producers
have lower serum uric acid (-10.2 %, P = 0.001),
TAG (-29.5 %, P = 0.007) and waist:hip ratio
(-2.6 %, P = 0.032), and that they also tended to
have higher high-density lipoprotein (HDL) choles-
terol (6.3 %, P = 0.069) compared with equol non-
producers (Guo et al. 2010). Other similar work
demonstrated that the benefits of soya isoflavones in
preventing CVD may be apparent among equol
producers only. Thus, in 572 Chinese adults, com-
pared with non-producers, equol producers showed
significantly lower serum TAG (-38.2, P = 0.012)
and common carotid artery intima-media thickness
(CCA-IMT) (-4.9 %, P = 0.033) (Cai et al. 2012).
However, in a recent study of 85 hypercholesterolemic
American men and postmenopausal women, the soy
food intake reduced serum LDL cholesterol equally in
both equol producers and non-producers. However, in
equol producers, i.e. *35 % of this study population,
soy consumption had the added cardiovascular benefit
of maintaining higher HDL-cholesterol concentrations
than those seen in equol non-producers (Wong et al.
2012). Studies in Western hypercholesterolemic and/
or hypertensive volunteers revealed significant reduc-
tions in total cholesterol, LDL cholesterol, LDL:HDL
ratio, plasma triglycerides and lipoprotein(a) with the
soy diet. Systolic and diastolic blood pressure of
postmenopausal women also decreased and endothe-
lial function improved in the equol producers, whereas
systolic and diastolic blood pressure increased and
endothelial function deteriorated in the equol non-
producers (Meyer et al. 2004; Kreijkamp-Kaspers
et al. 2005). The results of another study showed that
the differences between the groups in concentrations
of plasma lipids, glucose or insulin, or in blood
pressure according to equol-producing status were not
significant. The postmenopausal women in this study
were younger (aged 46–70) than those in the study
carried out by Krijkamp-Kaspers et al. (aged 60–75).
The subjects in this study, therefore, were more likely
to have a low risk of CVD at the outset and,
consequently, differences with respect to equol status
may not be detected (Hall et al. 2006). The use of
isoflavones to supplement diet has led to excellent
results between equol producers and non-producers.
Thus, a randomized, controlled, parallel study design
was carried out on 62 adults with hypercholesterol-
emia who consumed a novel soy germ pasta, naturally
enriched in isoflavone aglycones. The pasta delivered
33 mg of isoflavones and negligible soy protein and
led to a serum isoflavone concentration of
222 ± 21 nmol/L. Soy germ pasta reduced serum
total and LDL cholesterol by 0.47 ± 0.13 mmol/L
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(P = 0.001) and 0.36 ± 0.10 mmol/L (P = 0.002)
more than conventional pasta, which represent reduc-
tions from baseline of 7.3 % (P = 0.001) and 8.6 %
(P = 0.002), respectively. Arterial stiffness
(P = 0.003) and high-sensitivity C-reactive protein
(hsCRP) (P = 0.03) decreased and improvements in
all of the above risk markers were greatest in equol
producers. It is likely that pasta naturally enriched
with isoflavone aglycones and lacking soy protein had
a significant hypocholesterolemic effect. Thus, the
number of equol producers was very high (69 %),
greater than in early studies, because daidzein-metab-
olizing bacteria could help to improve risk markers
(Clerici et al. 2007).
The most recent study aimed at confirming the
importance of being an equol producer was carried out
on 54 overweight or obese Japanese outpatients, who
orally ingested placebo or natural S-equol tablets
containing 10 mg S-equol for 12 weeks. This treat-
ment led to a significant decrease in glycosylated
hemoglobin (HbA1c), serum LDL cholesterol levels
and cardio-ankle vascular index (CAVI) score, indi-
cating that equol might have a role in glycemic control
and in the prevention of cardiovascular disease (Usui
et al. 2013). In this study, differences between equol
producers and non-producers were not found, because
equol intake did not allow an estimation of the
presence of daidzein-metabolizing bacteria, but it did
confirm the importance of being an equol producer due
to the beneficial effect of S-equol.
Soy-based diets have also been reported to protect
against the development of atherosclerosis, another
cardiovascular risk factor. To examine the potential
benefit of these compounds on atherosclerosis progres-
sion, Curtis et al. (2013) designed a double-blind,
parallel-design, placebo-controlled trial that was con-
ducted on 93 postmenopausal women with type 2
diabetes mellitus. The subjects were randomly assigned
to a split dose of 27 g flavonoid-enriched chocolate/d
[850 mg flavan-3-ols (90 mg epicatechin) ? 100 mg
isoflavones (aglycone equivalents)/d] or matched pla-
cebo. It was found that equol producers (n = 17)
experienced larger reductions in diastolic blood
pressure, mean arterial pressure and pulse wave
velocity (-2.24 ± 1.31, -1.24 ± 1.30 mm Hg, and
-0.68 ± 0.40 m/s, respectively; P \ 0.01) compared
with non-equol producers (n = 30).
Studies in animals have demonstrated that soy-based
diets containing phytoestrogens afford protection
against CVD. Several models have been developed to
study different risk factors. In some studies it was
established that feeding a soy isoflavone-rich diet during
pregnancy, weaning and postweaning affords cardio-
vascular protection in aged male rats. Notably, rats
exposed to a soy isoflavone-deficient diet throughout
pregnancy and adult life exhibited increased oxidative
stress, diminished antioxidant enzyme and endothelial
nitric oxide synthase (eNOS) levels, endothelial dys-
function, and elevated blood pressure in vivo. The
beneficial effects of refeeding isoflavones to isoflavone-
deficient rats include an increased production of nitric
oxide and endothelium-derived hyperpolarizing factor
(EDHF), an upregulation of antioxidant defense
enzymes and lowering of blood pressure in vivo (Bon-
acasa et al. 2011). In another study performed on human
platelets, it was found that equol has biological effects
attributable to thromboxane A(2) receptor antagonism
and this compound could therefore have beneficial
effects in the prevention of thrombotic events (Munoz
et al. 2009).
Estrogen or estrogen-related molecules as such
equol seem to protect women from left ventricular
hypertrophy, and recent evidence suggests that this
effect is mediated by estrogen receptor (ER) (Joy et al.
2006).
The mechanisms that contribute to the atheropro-
tective effects of a soy-based diet were addressed
using apolipoprotein E knock-out (apoE-/-) mice
fed with soy protein isolate associated with or without
phytochemicals or casein. The results showed that
atherosclerotic lesions were reduced in aortic sinus.
Plasma lipid profiles did not differ among the 3 groups,
suggesting that alternative mechanism(s) could have
contributed to the atheroprotective effect of soy-based
diets. Analysis of proximal aorta showed reduced
expression of monocyte chemoattractant protein-1
(MCP-1), a monocyte chemokine, in mice fed with
both soy-based diets compared with the casein fed
mice. In an in vitro lipopolysaccharide (LPS) induced
inflammation model, equol dose-dependently inhib-
ited LPS-induced MCP-1 secretion by macrophages,
suggesting a role for soy isoflavones in the protective
in vivo effects. Collectively, these findings suggest
that the reduction in atherosclerotic lesions observed
in mice fed with the soy-based diet is mediated in part
by inhibition of MCP-1, which could result in reduced
monocyte migration, an early event during atherogen-
esis (Nagarajan et al. 2008).
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Prostate cancer chemoprevention
The incidence rate of prostate cancer has been reported
to be lower in Asian than Western populations.
Traditional Asian food, which is high in soybean
products, may be associated with this decreased risk of
prostate cancer (Akaza 2012; Sugiyama et al. 2013).
The results of some studies have attributed to equol a
lower risk of prostate cancer (Jackson et al. 2010;
Miyanaga et al. 2012), whereas other studies have
implicated other isoflavones (Park et al. 2009; Travis
et al. 2009). Only two assays have been carried out on
the influence that isoflavones have on the risk of prostate
cancer in equol producers. Jackson et al. (2010)
evaluated the relationship between spot urinary con-
centrations of phytoestrogens and total prostate cancer
and tumor grade in a hospital-based case–control study
in Jamaica and they found that producers of equol have a
lower risk of total- and high-grade prostate cancer,
although these patients did not intake supplemented
isoflavones. Another case–control study concerned the
prostate cancer risk based on isoflavone intake (60 mg/
day) and equol production for 12 months in 158
Japanese men aged between 50 and 75 years. The
results showed that, for the 53 patients aged 65 or more,
the incidence of cancer in the isoflavone group was
significantly lower than that in the placebo group (28.0
vs. 57.1 %, P = 0.031). Isoflavone intake proved to
have an effect on prostate cancer, even though Japanese
ordinarily ingest considerable amounts of isoflavone in
daily life. One would expect that this effect would be
even more marked in Europe and America, where the
isoflavone intake is much lower (Miyanaga et al. 2012).
However, studies performed in these regions did not
find any relation between equol and the risk of prostate
cancer, probably due to the low isoflavone levels present
in the diet (Venkitaraman et al. 2008; Ward et al. 2008a;
Park et al. 2009). The preventive effect of isoflavones
could be due to the fact that prostate tissue may have the
ability to concentrate dietary soy isoflavones to poten-
tially anti-carcinogenic levels (Gardner et al. 2009).
Initial studies in animals, such as that carried out by
Landström et al. (1998) showed that soy flour inhibits
implanted prostate cancer growth in prostate tumors
transplanted in 125 rats. This effect is due to the
significant increase in daily urinary excretion of the
isoflavonoids, daidzein, O-desmethylangolensin,
equol and genistein in the rats fed with soy flour.
Other authors showed that equol administration in rats
reduces prostate-specific antigen levels from human
prostate cancer (LNCap) cells under 5alpha-dihydro-
testosterone (5alpha-DHT) stimulation, decreases rat
prostate size, decreases serum 5alpha-DHT levels and
androgen hormone action, while not altering other
circulating sex steroids or luteinizing hormone levels
(Lund et al. 2011).
A model of benign and malignant prostatic epithe-
lial cells in vitro suggests that equol inhibited growth
of benign human prostatic epithelial cells by 37 % at
10-6 M and 80 % at 10-5 M (Hedlund et al. 2003).
This effect could be due to the presence of equol-
modulated genes in multiple cellular pathways,
including the cell-cycle pathway genes. Equol effect
androgen-responsive genes, IGF-1 pathway gene and
MAP kinase-related pathway gene are known to be
active mediators of prostate cancer cell proliferative
activity and the inhibition of these pathways would be
consistent with an inhibitory effect on LNCaP cell
growth (Magee et al. 2006; Takahashi et al. 2006).
Equol also enhanced the growth inhibitory effect of
estrogen-related receptor (ERR)-c on prostate cancer
(PC)-3 cells, indicating that it inhibits invasion in
prostate cancer DU145 cells possibly via down-
regulation of matrix metalloproteinase-9, matrix
metalloproteinase-2 and urokinase-type plasminogen
activator by antioxidant activity (Hirvonen et al. 2011;
Zheng et al. 2012).
Breast cancer chemoprevention
It appears that equol producer patients have a lower risk
of developing breast cancer than those subjects who do
not have this capability. This behavior has been
demonstrated in several Meta-analyses, where the
protective effect appears to be more evident in Asian
women than in those living in Western populations
(Wu et al. 2008; Dong and Qin 2011; Zhong and Zhang
2012). While these studies showed that the intake of
isoflavones reduced the risk of developing breast
cancer, another study of 237 European women with
estrogen receptor-positive tumors indicated that the
risk of breast cancer was increased with higher levels of
urinary equol [odds ratio 1.07 (95 % confidence
interval 1.01–1.12), P = 0.013] (Ward et al. 2008b).
This finding is consistent with the findings of another
study, where isoflavone supplements were found to
increase the progression of estrogen-dependent tumors
(Tonetti et al. 2007).
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One of the hypothesized protective mechanisms of
soy against breast cancer involves changes in estrogen
metabolism to 2-hydroxy (OH) and 16a-OH estro-
gens. In this respect, Morimoto et al. (2012) examined
the effect of soy foods on the 2:16a-OH E(1) ratio
among premenopausal women during a randomized,
crossover intervention study in which women were
stratified by equol producer status. Similar non-
significant increases in the 2:16a-OH E(1) ratio were
observed in equol producers (P = 0.13) and non-
producers (P = 0.23). These findings suggest a ben-
eficial influence of soy foods on estrogen metabolism
regardless of equol producer status.
In an effort to confirm the results of an earlier study
showing premenopausal equol producers to have
hormone profiles associated with reduced breast
cancer risk, and to investigate whether equol excretion
status and plasma hormone concentrations can be
influenced by consumption of probiotics, Bonorden
et al. (2004) performed a randomized, single-blind,
placebo-controlled, parallel-arm trial in 34 subjects. It
was found that consumption of Lactobacillus aci-
dophilus and Bifidobacterium longum did not alter
urinary equol excretion and plasma reproductive
hormones in premenopausal women, probably
because these bacteria did not have the capacity to
metabolize daidzein. Other study in postmenopausal
women with an intake of a particular probiotic
supplement did not generally show an effect on
plasma isoflavones, although the large differences
between plasma and urinary equol in some subjects
suggest that equol producer status may be modifiable
in some individuals (Nettleton et al. 2004).
Mammographic density is often used as a bio-
marker for breast cancer risk. This characteristic
represents the amount of stromal and glandular tissue
in the female breast. High mammographic density has
been associated with a three- to six-fold increase in
breast cancer risk. Only a few intervention studies
concerning isoflavones from soy or other sources and
mammographic density have been published. Equol
excretion status could be related with mammographic
density. In a trial that involved 55 sedentary, American
postmenopausal women, aged 50–75 years, mammo-
graphic density was 39 % lower in equol producers
compared with non-producers (P = 0.04). This result
suggests that particular intestinal bacterial profiles are
associated with postmenopausal mammographic den-
sity (Frankenfeld et al. 2004). This study does have
some limitations, such as the small sample of women,
and the authors were not able to estimate precisely the
magnitude of the association between daidzein-metab-
olizing phenotypes and mammographic density.
Another study was carried out on 175 Dutch post-
menopausal women, aged 60–75 years, to compare
the effects of soy protein intake, with 99 mg isoflav-
ones administered daily with an intake of milk protein
(placebo) for 1 year. The results showed that mam-
mographic density decreased in both study arms, but
the decrease did not differ significantly between
intervention and placebo groups, where equol pro-
ducer status did not modify the results (Verheus et al.
2008). Differences in the microflora between over-
weight subjects and those with normal weights could
be responsible for these contradictions. Atkinson et al.
(2009) did not find any associations between daidzein-
metabolizing phenotypes and breast density in 200
premenopausal women in the United States, probably
because of low-soy consumption.
New insights into the benefits of equol-producing
bacteria
Equol producer status has been linked with the
prevention of other pathologies, such as gastrointes-
tinal disorders, and a healthy diet based on soy food
intake appears to maintain health in subjects over
many years.
Considering the gastrointestinal tract, it is known
that hydrogen gas produced during colonic fermenta-
tion is excreted in breath and flatus, or removed by
hydrogen-consuming bacteria such as methanogens
and sulfate-reducing bacteria. A recent study showed
that the equol-producing activity of the microbial
consortium EPC4 attenuated the methanogenesis and
sulphidogenesis of active hydrogen-consuming bacte-
ria under in vitro simulated gastro-intestinal condi-
tions. These findings are relevant in terms of
abdominal discomfort such as bloating and flatulence
and highlight the potential of these bacteria as a
probiotic for the stimulation of equol production and
the concomitant decrease of undesirable methane and
hydrogen sulfide production (Bolca and Verstraete
2010). This factor could be important in other diseases
of the gastrointestinal tract, such as inflammatory
bowel disease, irritable bowel disease and obesity, in
which methane and hydrogen sulfide producer bacteria
could be involved.
Phytochem Rev (2013) 12:979–1000 993
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A recent study (Hozawa et al. 2013) has related
isoflavone intake with disability and death. The
researchers used a nested case–control study to
compare serum isoflavone (daidzein, genistein, glyci-
tein and equol) levels in 165 participants that died or
were certified as disabled and 177 controls. It was
found that higher serum equol levels, but not any other
isoflavones, were inversely associated with the com-
posite endpoint of disability and death. The proportion
of cases was lower in the group with the highest levels
of equol (34/91, 37 %) compared with equol nonpro-
ducers (84/161, 52 %). The risk of disability or death
among equol producers remained reduced after
adjusting for age and sex. However, the correlation
between equol levels and the bone mineral density of
the calcaneus was not significant. Furthermore,
adjusting for bone mineral density did not alter the
risk of the composite endpoint of death and disability.
Therefore, other mechanisms may play a role and
should also be considered. Unfortunately, the
researchers’ did not have any information regarding
the causes of disability or mortality and, consequently,
they were not able to clarify the factors associated with
reducing the risk of the composite endpoint in the
higher equol group than the other groups. According to
the Health Report published in 2004 by the World
Health Organization, both healthy life expectancy at
age 0 and 60 years were the highest in Japan compared
with all other countries in the world and, although it
cannot be concluded that equol producer status is
involved, higher equol levels appear to be associated
with better health. Further studies, including random-
ized controlled trials, aimed at clarifying the role of
equol in overall health are warranted.
Conclusions
The importance of equol has increased in recent years
due to the beneficial effects on human health, since it
has antioxidants, improve the symptoms associated
with the menopause (both hot flushes and osteoporo-
sis), modulate cardiovascular risk, and are chemopre-
ventive in prostate cancer. The chemoprevention in
breast cancer is more controversial, whereas the intake
of isoflavones over time can prevent breast cancer or,
one established, it may accelerate the progression of
estrogen-dependent tumor. It is clear that the long-
term intake of soy food is necessary to obtain higher
yields of these compounds, so their effects are more
evident in Asian populations than in Western popu-
lations. Microflora play an important role because they
metabolize these parent compounds to more active
metabolites. The different compositions of the micro-
flora according to sex, ethnic race, age, obesity and the
geographic distribution affect the metabolism of
isoflavones. The Coriobacteriaceae and Clostridia-
ceae families have been linked with the metabolism of
these compounds, but it is necessary to carry out
further studies to investigate these bacteria. The
recently developed pyrosequencing techniques could
help to discover equol producer bacteria that cannot be
cultured and also the genes responsible for the
metabolism of these compounds. The isolation of
equol-producing probiotic bacteria could also be used
to convert equol nonproducers to equol producers,
since the effects on human health of these compounds
are stronger in the equol producer population.
Acknowledgments The work described in this paper was
supported by the Consejerı́a de Innovación, Ciencia y Empresa,
Junta de Andalucı́a (Project P10-AGR5822) and the Ministerio
de Ciencia e Innovación, Spain (Project No AGL2009-08864/
AGR).
References
Akaza H (2012) Prostate cancer chemoprevention by soy iso-
flavones: role of intestinal bacteria as the ‘‘second human
genome’’. Cancer Sci 103:969–975
Arora A, Nair MG, Strasburg GM (1998) Antioxidant activities
of isoflavones and their biological metabolites in a lipo-
somal system. Arch Biochem Biophys 356:133–141
Arora A, Byrem TM, Nair MG, Strasburg GM (2000) Modu-
lation of liposomal membrane fluidity by flavonoids and
isoflavonoids. Arch Biochem Biophys 373:102–109
Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T,
Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM,
Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L,
Hansen T, Hattori M, Hayashi T, Kleerebezem M,
Kurokawa K, Leclerc M, Levenez F, Manichanh C, Niel-
sen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-
Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG,
Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S,
Dore J, Meta HITC, Antolin M, Artiguenave F, Blottiere
HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone
A, Delorme C, Denariaz G, Dervyn R, Foerstner KU, Friss
C, van de Guchte M, Guedon E, Haimet F, Huber W, van
Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, La-
khdari O, Layec S, Le Roux K, Maguin E, Merieux A, Melo
Minardi R, M’Rini C, Muller J, Oozeer R, Parkhill J, Re-
nault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A,
994 Phytochem Rev (2013) 12:979–1000
123
Turner K, Vandemeulebrouck G, Varela E, Winogradsky
Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P (2011)
Enterotypes of the human gut microbiome. Nature
473:174–180
Aso T, Uchiyama S, Matsumura Y, Taguchi M, Nozaki M,
Takamatsu K, Ishizuka B, Kubota T, Mizunuma H, Ohta H
(2012) A natural S-equol supplement alleviates hot flushes
and other menopausal symptoms in equol nonproducing
postmenopausal Japanese women. J Womens Health
(Larchmt) 21:92–100
Atkinson C, Berman S, Humbert O, Lampe JW (2004) In vitro
incubation of human feces with daidzein and antibiotics
suggests interindividual differences in the bacteria
responsible for equol production. J Nutr 134:596–599
Atkinson C, Newton KM, Aiello Bowles EJ, Lehman CD,
Stanczyk FZ, Westerlind KC, Li L, Lampe JW (2009)
Daidzein-metabolizing phenotypes in relation to mam-
mographic breast density among premenopausal women in
the United States. Breast Cancer Res Treat 116:587–594
Atkinson C, Newton KM, Yong M, Stanczyk FZ, Westerlind
KC, Li L, Lampe JW (2012) Daidzein-metabolizing phe-
notypes in relation to bone density and body composition
among premenopausal women in the United States.
Metabolism 61:1678–1682
Bandara M, Arun SJ, Allanson M, Widyarini S, Chai Z, Reeve
VE (2010) Topical isoflavonoids reduce experimental
cutaneous inflammation in mice. Immunol Cell Biol
88:727–733
Barnes S, Sfakianos J, Coward L, Kirk M (1996) Soy isoflavo-
noids and cancer prevention. Underlying biochemical and
pharmacological issues. Adv Exp Med Biol 401:87–100
Barnes S, Prasain J, D’Alessandro T, Arabshahi A, Botting N,
Lila MA, Jackson G, Janle EM, Weaver CM (2011) The
metabolism and analysis of isoflavones and other dietary
polyphenols in foods and biological systems. Food Funct
2:235–244
Bolca S, Verstraete W (2010) Microbial equol production
attenuates colonic methanogenesis and sulphidogenesis
in vitro. Anaerobe 16:247–252
Bonacasa B, Siow RC, Mann GE (2011) Impact of dietary soy
isoflavones in pregnancy on fetal programming of endo-
thelial function in offspring. Microcirculation 18:270–285
Bonorden MJ, Greany KA, Wangen KE, Phipps WR, Feirtag J,
Adlercreutz H, Kurzer MS (2004) Consumption of Lacto-
bacillus acidophilus and Bifidobacterium longum do not
alter urinary equol excretion and plasma reproductive
hormones in premenopausal women. Eur J Clin Nutr
58:1635–1642
Buus NH, Hansson NC, Rodriguez-Rodriguez R, Stankevicius
E, Andersen MR, Simonsen U (2011) Antiatherogenic
effects of oleanolic acid in apolipoprotein E knockout
mice. Eur J Pharmacol 670:519–526
Cai Y, Guo K, Chen C, Wang P, Zhang B, Zhou Q, Mei F, Su Y
(2012) Soya isoflavone consumption in relation to carotid
intima-media thickness in Chinese equol excretors aged
40–65 years. Br J Nutr 108:1698–1704
Chassard C, Dapoigny M, Scott KP, Crouzet L, Del’homme C,
Marquet P, Martin JC, Pickering G, Ardid D, Eschalier A,
Dubray C, Flint HJ, Bernalier-Donadille A (2012) Func-
tional dysbiosis within the gut microbiota of patients with
constipated-irritable bowel syndrome. Aliment Pharmacol
Ther 35:828–838
Chen KI, Erh MH, Su NW, Liu WH, Chou CC, Cheng KC
(2012) Soyfoods and soybean products: from traditional
use to modern applications. Appl Microbiol Biotechnol
96:9–22
Cheng K-C, Lin J-T, Wu J-Y, Liu W-H (2010) Isoflavone
conversion of black soybean by immobilized Rhizopus spp.
Food Biotechnol 24:312–331
Chien HL, Huang HY, Chou CC (2006) Transformation of
isoflavone phytoestrogens during the fermentation of soy-
milk with lactic acid bacteria and bifidobacteria. Food
Microbiol 23:772–778
Chiou RY, Cheng SL (2001) Isoflavone transformation during
soybean koji preparation and subsequent miso fermenta-
tion supplemented with ethanol and NaCl. J Agric Food
Chem 49:3656–3660
Choi EJ (2009a) Chronic equol administration attenuates the
antioxidant defense system and causes apoptosis in the
mouse brain. Food Chem Toxicol 47:1779–1784
Choi EJ (2009b) Evaluation of equol function on anti- or pro-
oxidant status in vivo. J Food Sci 74:H65–H71
Chung JE, Kim SY, Jo HH, Hwang SJ, Chae B, Kwon DJ, Lew
YO, Lim YT, Kim JH, Kim EJ, Kim JH, Kim MR (2008)
Antioxidant effects of equol on bovine aortic endothelial
cells. Biochem Biophys Res Commun 375:420–424
Clerici C, Setchell KD, Battezzati PM, Pirro M, Giuliano V,
Asciutti S, Castellani D, Nardi E, Sabatino G, Orlandi S,
Baldoni M, Morelli O, Mannarino E, Morelli A (2007)
Pasta naturally enriched with isoflavone aglycons from soy
germ reduces serum lipids and improves markers of car-
diovascular risk. J Nutr 137:2270–2278
Crawford SL, Jackson EA, Churchill L, Lampe JW, Leung K,
Ockene JK (2013) Impact of dose, frequency of adminis-
tration, and equol production on efficacy of isoflavones for
menopausal hot flashes: a pilot randomized trial. Menopause
Crozier A, Jaganath IB, Clifford MN (2009) Dietary phenolics:
chemistry, bioavailability and effects on health. Nat Prod
Rep 26:1001–1043
Curtis PJ, Potter J, Kroon PA, Wilson P, Dhatariya K, Sampson
M, Cassidy A (2013) Vascular function and atherosclerosis
progression after 1 y of flavonoid intake in statin-treated
postmenopausal women with type 2 diabetes: a double-
blind randomized controlled trial. Am J Clin Nutr
97:936–942
Decroos K, Vanhemmens S, Cattoir S, Boon N, Verstraete W
(2005) Isolation and characterisation of an equol-produc-
ing mixed microbial culture from a human faecal sample
and its activity under gastrointestinal conditions. Arch
Microbiol 183:45–55
Doerge D, Chang H, Churchwell M, Holder C (2000) Analysis
of soy isoflavone conjugation in vitro and in human blood
using liquid chromatography-mass spectrometry. Drug
Metab Dispos 3:298–307
Dong JY, Qin LQ (2011) Soy isoflavones consumption and risk
of breast cancer incidence or recurrence: a meta-analysis of
prospective studies. Breast Cancer Res Treat 125:315–323
Franke AA, Halm BM, Ashburn LA (2008) Isoflavones in
children and adults consuming soy. Arch Biochem Biophys
476:161–170
Phytochem Rev (2013) 12:979–1000 995
123
Frankenfeld CL (2011) O-desmethylangolensin: the importance
of equol’s lesser known cousin to human health. Adv Nutr
2:317–324
Frankenfeld CL, McTiernan A, Aiello EJ, Thomas WK, LaC-
roix K, Schramm J, Schwartz SM, Holt VL, Lampe JW
(2004) Mammographic density in relation to daidzein-
metabolizing phenotypes in overweight, postmenopausal
women. Cancer Epidemiol Biomarkers Prev 13:1156–1162
Fujimoto K, Tanaka M, Hirao Y, Nagata Y, Mori M, Miyanaga
N, Akaza H, Kim WJ (2008) Age-stratified serum levels of
isoflavones and proportion of equol producers in Japanese
and Korean healthy men. Prostate Cancer Prostatic Dis
11:252–257
Gardana C, Canzi E, Simonetti P (2009) The role of diet in the
metabolism of daidzein by human faecal microbiota sam-
pled from Italian volunteers. J Nutr Biochem 20:940–947
Gardner CD, Oelrich B, Liu JP, Feldman D, Franke AA, Brooks
JD (2009) Prostatic soy isoflavone concentrations exceed
serum levels after dietary supplementation. Prostate
69:719–726
Gold EB, Sternfeld B, Kelsey JL, Brown C, Mouton C, Reame
N, Salamone L, Stellato R (2000) Relation of demographic
and lifestyle factors to symptoms in a multi-racial/ethnic
population of women 40–55 years of age. Am J Epidemiol
152:463–473
Guo K, Zhang B, Chen C, Uchiyama S, Ueno T, Chen Y, Su Y
(2010) Daidzein-metabolising phenotypes in relation to
serum lipids and uric acid in adults in Guangzhou, China.
Br J Nutr 104:118–124
Hall WL, Vafeiadou K, Hallund J, Bugel S, Reimann M,
Koebnick C, Zunft HJ, Ferrari M, Branca F, Dadd T, Talbot
D, Powell J, Minihane AM, Cassidy A, Nilsson M, Dahl-
man-Wright K, Gustafsson JA, Williams CM (2006) Soy-
isoflavone-enriched foods and markers of lipid and glucose
metabolism in postmenopausal women: interactions with
genotype and equol production. Am J Clin Nutr 83:592–600
Hedlund TE, Johannes WU, Miller GJ (2003) Soy isoflavonoid
equol modulates the growth of benign and malignant
prostatic epithelial cells in vitro. Prostate 54:68–78
Hirvonen J, Rajalin AM, Wohlfahrt G, Adlercreutz H, Wahala
K, Aarnisalo P (2011) Transcriptional activity of estrogen-
related receptor gamma (ERRgamma) is stimulated by the
phytoestrogen equol. J Steroid Biochem Mol Biol
123:46–57
Horii K, Adachi T, Matsuda T, Tanaka T, Sahara H, Shibasaki S,
Ogino C, Hata Y, Ueda M, Kondo A (2009) Improvement
of isoflavone aglycones production using b-glucosidase
secretory produced in recombinant Aspergillus oryzae.
J Mol Catal B Enzym 59:297–301
Hozawa A, Sugawara Y, Tomata Y, Kakizaki M, Tsuboya T,
Ohmori-Matsuda K, Nakaya N, Kuriyama S, Fukao A,
Tsuji I (2013) Relationship Between Serum Isoflavone
Levels and Disability-Free Survival Among Community-
Dwelling Elderly Individuals: nested Case-Control Study
of the Tsurugaya Project. J Gerontol Ser A Biol Sci Med
Sci 68:465–472
Hur HG, Lay JO, Beger RD, Freeman JP, Rafii F (2000) Isola-
tion of human intestinal bacteria metabolizing the natural
isoflavone glycosides daidzin and genistin. Arch Microbiol
174:422–428
Hur HG, Beger RD, Heinze TM, Lay JO Jr, Freeman JP, Dore J,
Rafii F (2002) Isolation of an anaerobic intestinal bacte-
rium capable of cleaving the C-ring of the isoflavonoid
daidzein. Arch Microbiol 178:8–12
Hwang J, Wang J, Morazzoni P, Hodis HN, Sevanian A (2003)
The phytoestrogen equol increases nitric oxide availability
by inhibiting superoxide production: an antioxidant
mechanism for cell-mediated LDL modification. Free
Radic Biol Med 34:1271–1282
Ishimi Y (2010) Dietary equol and bone metabolism in post-
menopausal Japanese women and osteoporotic mice. J Nutr
140:1373S–1376S
Ismail B, Hayes K (2005) Beta-glycosidase activity toward
different glycosidic forms of isoflavones. J Agric Food
Chem 53:4918–4924
Izumi T, Piskula MK, Osawa S, Obata A, Tobe K, Saito M,
Kataoka S, Kubota Y, Kikuchi M (2000) Soy isoflavone
aglycones are absorbed faster and in higher amounts than
their glucosides in humans. J Nutr 130:1695–1699
Jackson MD, McFarlane-Anderson ND, Simon GA, Bennett FI,
Walker SP (2010) Urinary phytoestrogens and risk of
prostate cancer in Jamaican men. Cancer Causes Control
21:2249–2257
Jackson RL, Greiwe JS, Schwen RJ (2011) Ageing skin: oest-
rogen receptor beta agonists offer an approach to change
the outcome. Exp Dermatol 20:879–882
Jenks BH, Iwashita S, Nakagawa Y, Ragland K, Lee J, Carson
WH, Ueno T, Uchiyama S (2012) A pilot study on the
effects of S-equol compared to soy isoflavones on meno-
pausal hot flash frequency. J Womens Health (Larchmt)
21:674–682
Jin JS, Nishihata T, Kakiuchi N, Hattori M (2008) Biotrans-
formation of C-glucosylisoflavone puerarin to estrogenic
(3S)-equol in co-culture of two human intestinal bacteria.
Biol Pharm Bull 31:1621–1625
Jin JS, Kitahara M, Sakamoto M, Hattori M, Benno Y (2010)
Slackia equolifaciens sp. nov., a human intestinal bacte-
rium capable of producing equol. Int J Syst Evol Microbiol
60:1721–1724
Jou HJ, Wu SC, Chang FW, Ling PY, Chu KS, Wu WH
(2008) Effect of intestinal production of equol on
menopausal symptoms in women treated with soy iso-
flavones. Int J Gynaecol Obstet 102:44–49
Joy S, Siow RC, Rowlands DJ, Becker M, Wyatt AW, Aa-
ronson PI, Coen CW, Kallo I, Jacob R, Mann GE
(2006) The isoflavone Equol mediates rapid vascular
relaxation: Ca2?-independent activation of endothelial
nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt
phosphorylation in human endothelial cells. J Biol Chem
281:27335–27345
Kamiyama M, Kishimoto Y, Tani M, Utsunomiya K, Kondo K
(2009) Effects of equol on oxidized low-density lipopro-
tein-induced apoptosis in endothelial cells. J Atheroscler
Thromb 16:239–249
Kaya M, Ito J, Kotaka A, Matsumura K, Bando H, Sahara H,
Ogino C, Shibasaki S, Kuroda K, Ueda M, Kondo A, Hata
Y (2008) Isoflavone aglycones production from isoflavone
glycosides by display of beta-glucosidase from Aspergillus
oryzae on yeast cell surface. Appl Microbiol Biotechnol
79:51–60
996 Phytochem Rev (2013) 12:979–1000
123
Kelly GE, Joannou GE, Reeder AY, Nelson C, Waring MA
(1995) The variable metabolic response to dietary iso-
flavones in humans. Proc Soc Exp Biol Med 208:40–43
Kolodziejczyk-Czepas J (2012) Trifolium species-derived sub-
stances and extracts–biological activity and prospects for
medicinal applications. J Ethnopharmacol 143:14–23
Kreijkamp-Kaspers S, Kok L, Bots ML, Grobbee DE, Lampe
JW, van der Schouw YT (2005) Randomized controlled
trial of the effects of soy protein containing isoflavones on
vascular function in postmenopausal women. Am J Clin
Nutr 81:189–195
Landstrom M, Zhang JX, Hallmans G, Aman P, Bergh A,
Damber JE, Mazur W, Wahala K, Adlercreutz H (1998)
Inhibitory effects of soy and rye diets on the development
of Dunning R3327 prostate adenocarcinoma in rats. Pros-
tate 36:151–161
Lun-Cheng K, Kung-Ta L (2008) Cloning, expression, and
characterization of two b-glucosidases from isoflavone
glycoside-hydrolyzing Bacillus subtilis natto. J Agric Food
Chem 1:119–125
Lund TD, Blake C, Bu L, Hamaker AN, Lephart ED (2011)
Equol an isoflavonoid: potential for improved prostate
health, in vitro and in vivo evidence. Reprod Biol Endo-
crinol 9:4
Maccaferri S, Biagi E, Brigidi P (2011) Metagenomics: key to
human gut microbiota. Dig Dis 29:525–530
Magee PJ, Raschke M, Steiner C, Duffin JG, Pool-Zobel BL,
Jokela T, Wahala K, Rowland IR (2006) Equol: a com-
parison of the effects of the racemic compound with that of
the purified S-enantiomer on the growth, invasion, and
DNA integrity of breast and prostate cells in vitro. Nutr
Cancer 54:232–242
Malaivijitnond S (2012) Medical applications of phytoestrogens
from the Thai herb Pueraria mirifica. Front Med 6:8–21
Malashree L, Mudgil P, Dagar SS, Kumar S, Puniya AK (2012)
b-Glucosidase activity of lactobacilli for biotransformation
of Soy Isoflavones. Food Biotechnol. (Philadelphia, PA,
US) 26: 154–163
Marazza JA, Nazareno MA, de Giori GS, Garro MS (2012)
Enhancement of the antioxidant capacity of soymilk by
fermentation with Lactobacillus rhamnosus. Journal of
Functional Foods 4:594–601
Marteau P (2009) Bacterial flora in inflammatory bowel disease.
Dig Dis 27(Suppl 1):99–103
Maruo T, Sakamoto M, Ito C, Toda T, Benno Y (2008) Ad-
lercreutzia equolifaciens gen. nov., sp. nov., an equol-
producing bacterium isolated from human faeces, and
emended description of the genus Eggerthella. Int J Syst
Evol Microbiol 58:1221–1227
Mase T, Mori S, Yokoe M (2004) Purification, Characterization,
and a Potential Application of b-Glucosidase from Asper-
gillus pulverulentus YM-80. J Appl Glycosci 211–216
Masilamani M, Wei J, Sampson HA (2012) Regulation of the
immune response by soybean isoflavones. Immunol Res
54:95–110
Matsuura M, Obata A (1993) Beta-glucosidases from soybeans
hydrolyze daidzin and genistin. J Food Sci 58:144–147
Matthies A, Blaut M, Braune A (2009) Isolation of a human
intestinal bacterium capable of daidzein and genistein
conversion. Appl Environ Microbiol 75:1740–1744
Meyer BJ, Larkin TA, Owen AJ, Astheimer LB, Tapsell LC,
Howe PR (2004) Limited lipid-lowering effects of regular
consumption of whole soybean foods. Ann Nutr Metab
48:67–78
Miyanaga N, Akaza H, Hinotsu S, Fujioka T, Naito S, Namiki
M, Takahashi S, Hirao Y, Horie S, Tsukamoto T, Mori M,
Tsuji H (2012) Prostate cancer chemoprevention study: an
investigative randomized control study using purified iso-
flavones in men with rising prostate-specific antigen.
Cancer Sci 103:125–130
Morimoto Y, Conroy SM, Pagano IS, Isaki M, Franke AA,
Nordt FJ, Maskarinec G (2012) Urinary estrogen metabo-
lites during a randomized soy trial. Nutr Cancer
64:307–314
Munoz Y, Garrido A, Valladares L (2009) Equol is more active
than soy isoflavone itself to compete for binding to
thromboxane A(2) receptor in human platelets. Thromb
Res 123:740–744
Muthyala RS, Ju YH, Sheng S, Williams LD, Doerge DR,
Katzenellenbogen BS, Helferich WG, Katzenellenbogen
JA (2004) Equol, a natural estrogenic metabolite from soy
isoflavones: convenient preparation and resolution of R-
and S-equols and their differing binding and biological
activity through estrogen receptors alpha and beta. Bioorg
Med Chem 12:1559–1567
Nagarajan S, Burris RL, Stewart BW, Wilkerson JE, Badger TM
(2008) Dietary soy protein isolate ameliorates atheroscle-
rotic lesions in apolipoprotein E-deficient mice potentially
by inhibiting monocyte chemoattractant protein-1 expres-
sion. J Nutr 138:332–337
Nagata C, Ueno T, Uchiyama S, Nagao Y, Yamamoto S, Shi-
buya C, Kashiki Y, Shimizu H (2008) Dietary and lifestyle
correlates of urinary excretion status of equol in Japanese
women. Nutr Cancer 60:49–54
Nettleton JA, Greany KA, Thomas W, Wangen KE, Adlercreutz
H, Kurzer MS (2004) Plasma phytoestrogens are not
altered by probiotic consumption in postmenopausal
women with and without a history of breast cancer. J Nutr
134:1998–2003
Ohigashi S, Sudo K, Kobayashi D, Takahashi O, Takahashi T,
Asahara T, Nomoto K, Onodera H (2013) Changes of the
intestinal microbiota, short chain fatty acids, and fecal pH
in patients with colorectal cancer. Dig Dis Sci
Okabe Y, Shimazu T, Tanimoto H (2011) Higher bioavailability
of isoflavones after a single ingestion of aglycone-rich
fermented soybeans compared with glucoside-rich non-
fermented soybeans in Japanese postmenopausal women.
J Sci Food Agric 91:658–663
Otieno DO, Shah NP (2007) Endogenous beta-glucosidase and
beta-galactosidase activities from selected probiotic micro-
organisms and their role in isoflavone biotransformation in
soymilk. J Appl Microbiol 103:910–917
Park SY, Wilkens LR, Franke AA, Le Marchand L, Kakazu KK,
Goodman MT, Murphy SP, Henderson BE, Kolonel LN
(2009) Urinary phytoestrogen excretion and prostate can-
cer risk: a nested case-control study in the Multiethnic
Cohort. Br J Cancer 101:185–191
Park HY, Kim M, Han J (2011) Stereospecific microbial pro-
duction of isoflavanones from isoflavones and isoflavone
glucosides. Appl Microbiol Biotechnol 91:1173–1181
Phytochem Rev (2013) 12:979–1000 997
123
Parkar SG, Stevenson DE, Skinner MA (2008) The potential
influence of fruit polyphenols on colonic microflora and
human gut health. Int J Food Microbiol 124:295–298
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